Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06232538
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-01
First Post:
2024-01-22
Brief Title:
UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up
Sponsor:
Xinhua Hospital Shanghai Jiao Tong University School of Medicine
Organization:
Xinhua Hospital Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
A Prospective Multi-centre Single-blinded Study of UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Copy number variationCNV refers to ongoing chromosome segregation errors throughout consecutive cell divisions CNV is a hallmark of human cancer and it is associated with poor prognosis metastasis and therapeutic resistance Analyzing CNV of the DNA extracted from bile samples in gallbladder seems a promising method for diagnosing monitoring and predicting the prognosis of patients with gallbladder cancer CNV can be assessed using experimental techniques such as bulk DNA sequencing fluorescence in situ hybridization FISH or conventional karyotyping However these techniques are either time-consuming or non-specific The investigators here intend to study whether a new method named Ultrasensitive Chromosomal Aneuploidy Detection UCAD which is based on low-coverage whole-genome sequencing can be used to analyze CNV thus helping diagnose gallbladder cancer and assessing follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None